...who will retire from the trade group at year end. Amphivena Therapeutics Inc. said Curtis Ruegg...
...CEO. Guenot, who is a founder of the immuno-oncology company, will remain as an adviser. Ruegg...

...to develop and commercialize Navacims to treat Type I diabetes. Parvus President and CEO Curtis Ruegg...

...BioTherapeutics Inc. (NASDAQ:AGLE). Nanomedicine company Parvus Therapeutics Inc. (Burlingame, Calif.) said Chief Development Officer Curtis Ruegg...